Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech insider buys -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (108)	10/22/2005 7:35:15 AM
From: tom pope	Respond to of 213

There's also this, from Oct 14, which does not contradict the favorable implications of the more recent note, in fact possibly the opposite: Encysive Pharmaceuticals Inc. (ENCY) said Friday that Vice President of Finance Stephen L. Mueller entered two written plans to sell a total of up to 174,981 company shares. The Houston biopharmaceutical company said in a filing with the Securities and Exchange Commission that Mueller will sell 14,606 shares in March 2006 to pay taxes associated with the vesting of restricted stock and up to 160,375 shares through April 2006 if the stock price reaches pre-established levels. Encysive said that Mueller stated that his 10b5-1 plans "do not reflect a lack of confidence in the company" but reflect his aim to diversify his financial holdings and "avoid being prohibited from selling shares for long periods of time due to nonpublic information he may possess in the future." Rule 10b5-1 allows insiders to adopt agreements under which they can buy or sell their company's stock legally, even if they later acquire inside information. Encysive shares closed at $9.49 apiece on Friday, down 27 cents from Thursday's close.